The offering saw shares priced at $37.50, with pre-funded warrants sold at $37.499 to specific investors. By exercising their option for 1.6 million additional shares, underwriters signaled strong demand for the clinical-stage firm, which specializes in small molecule therapeutics.

Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays served as joint book-running managers for the transaction. Mizuho joined as a book-running manager, with LifeSci Capital, Baird, and Jones also participating in the management of the offering. The capital raise was conducted under a registration statement previously filed with the U.S. Securities and Exchange Commission in August 2025.